tirzepatide composition Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology Tirzepatide | C225H348N48O68 | CID
Description
Results from a meta-analysis of 22 randomised controlled trials across Medline and the Cochrane Library have suggested that tirzepatide (Mounjaro
Tirzepatide 30mg a dual GIP & GLP-1 receptor agonist studied for advanced research into glucose control, weight management, and metabolic health.
Book a consult today
ACCESS GLP-1 Program: Personalized care to improve wellness, support balanced blood sugar, and promote healthy, sustainable habits.
Immune Impact: The study also showed that semaglutide helps "reset" the liver's immune environment, restoring healthy T cell and B cell populations that are usually depleted by high-fat diets
Approved for adults and children 10+ with type 2 diabetes.
